Mechanism of iron potentiation of hepatic uroporphyria: studies in cultured chick embryo liver cells.
Effects of iron were studied in cultured chick embryo liver cells to help elucidate the effect of hepatic iron in the human disease porphyria cutanea tarda and in toxic porphyria caused by chemicals. These cultures have proven useful because (a) phenobarbital and phenobarbital-like drugs induce a common form(s) of cytochrome P-450 (P-450-phenobarbital) in these cultures; (b) 20-methylcholanthrene and certain other polycyclic hydrocarbons induce a different form(s) (P-450-methylchol-anthrene), and (c) uroporphyria can be produced rapidly by exposure to suitable chemicals. In these cultures, treatment with iron alone did not produce porphyrin accumulation, and treatment with iron + 5-aminolevulinate caused accumulation of protoporphyrin, as did treatment with 5-aminolevulinate alone. However, treatment with phenobarbital-like drugs and iron, the latter at a concentration as low as 0.2 microM, led to accumulation of uro- and heptacarboxylporphyrins. Potentiation of uroporphyrin accumulation by iron began before there was a detectable synergistic increase in activity of 5-aminolevulinate synthase, the rate-controlling enzyme of heme synthesis. In contrast, treatment of cultures with 20-methylcholanthrene, in the presence or absence of iron, did not result in uroporphyrin accumulation or an increase in the activity of 5-aminolevulinate synthase. Uroporphyrinogen decarboxylase activity was unchanged by drug and iron treatments. Inhibitors of P-450-phenobarbital, SKF525A and piperonyl butoxide, as well as cadmium and cycloheximide prevented the porphyrin accumulation produced by glutethimide + iron, even though, except with cycloheximide, these substances further increased 5-aminolevulinate synthase activity. In vitro, uroporphyrin was oxidized autocatalytically by iron. In intact hepatocytes, even low concentrations of iron (0.2 to 20 microM), in the presence of a form of cytochrome P-450 induced by phenobarbital-like chemicals, produces uroporphyria primarily by enhancing uroporphyrinogen oxidation, not by inhibition of the decarboxylase. Induction of 5-aminolevulinate synthase amplifies the porphyrin overproduction.
Department of Biochemistry, Emory University School of Medicine, Atlanta, Georgia 30322.
H L
HL
Bonkovsky
D000624:5-Aminolevulinate Synthetase / Q000378:metabolism; D000085:Acetates / Q000494:pharmacology*; D000438:Alcohols / Q000494:pharmacology; D000622:Aminolevulinic Acid / Q000494:pharmacology; D000818:Animals; D002478:Cells, Cultured; D002642:Chick Embryo; D002851:Chromatography, High Pressure Liquid; D004357:Drug Synergism; D005290:Ferric Compounds / Q000494:pharmacology*; D005984:Glutethimide / Q000494:pharmacology; D006419:Heme Oxygenase (Decyclizing) / Q000378:metabolism; D007536:Isomerism; D008099:Liver / Q000187:drug effects* / Q000201:enzymology; D008670:Metals / Q000494:pharmacology; D009571:Nitrilotriacetic Acid / Q000031:analogs & derivatives / Q000494:pharmacology*; D010084:Oxidation-Reduction; D010634:Phenobarbital / Q000494:pharmacology; D011083:Polycyclic Compounds / Q000494:pharmacology; D011166:Porphyrins / Q000378:metabolism*; D014578:Uroporphyrins / Q000378:metabolism*
D000085:Acetates; D000438:Alcohols; D005290:Ferric Compounds; D008670:Metals; D011083:Polycyclic Compounds; D011166:Porphyrins; D014578:Uroporphyrins; D000622:Aminolevulinic Acid; D005984:Glutethimide; D006419:Heme Oxygenase (Decyclizing); D000624:5-Aminolevulinate Synthetase; D009571:Nitrilotriacetic Acid; D010634:Phenobarbital; C020326:ferric nitrilotriacetate